Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study

D. Horakova, R. Zivadinov, B. Weinstock-Guttman, E. Havrdova, J. Qu, M. Tamaño-Blanco, D. Badgett, M. Tyblova, N. Bergsland, S. Hussein, L. Willis, J. Krasensky, M. Vaneckova, Z. Seidl, P. Lelkova, MG. Dwyer, M. Zhang, H. Yu, X. Duan, T....

. 2013 ; 8 (1) : e53996.

Language English Country United States

Document type Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't

Grant support
NT13237 MZ0 CEP Register

OBJECTIVES: To investigate the associations of environmental MS risk factors with clinical and MRI measures of progression in high-risk clinically isolated syndromes (CIS) after the first demyelinating event. METHODS: We analyzed 211 CIS patients (age: 28.9±7.8 years) enrolled in the SET study, a multi-center study of high-risk CIS patients. Pre-treatment samples were analyzed for IgG antibodies against cytomegalovirus (anti-CMV), Epstein Barr virus (EBV) early nuclear antigen-1 (EBNA-1), viral capsid antigen (VCA), early antigen-diffuse (EA-D), 25 hydroxy-vitamin D3 and cotinine levels and HLA DRB1*1501 status. The inclusion criteria required evaluation within 4 months of the initial demyelinating event, 2 or more brain MRI lesions and the presence of two or more oligoclonal bands in cerebrospinal fluid. All patients were treated with interferon-beta. Clinical and MRI assessments were obtained at baseline, 6, 12, and 24 months. RESULTS: The time to first relapse decreased and the number of relapses increased with anti-CMV IgG positivity. Smoking was associated with increased number and volume of contrast-enhancing lesions (CEL) during the 2-year period. The cumulative number of CEL and T2 lesions during the 2-year period was greater for individuals in the highest quartile of anti-EBV VCA IgG antibodies. The percent loss of brain volume was increased for those in the highest quartile of with anti-EBV VCA IgG antibodies. CONCLUSIONS: Relapses in CIS patients were associated with CMV positivity whereas anti-EBV VCA positivity was associated with progression on MRI measures, including accumulation of CEL and T2 lesions and development of brain atrophy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13031708
003      
CZ-PrNML
005      
20181023152659.0
007      
ta
008      
131002s2013 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0053996 $2 doi
035    __
$a (PubMed)23320113
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Horáková, Dana $u Department of Neurology and Center of Clinical Neuroscience, 1st Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. $7 xx0076527
245    10
$a Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study / $c D. Horakova, R. Zivadinov, B. Weinstock-Guttman, E. Havrdova, J. Qu, M. Tamaño-Blanco, D. Badgett, M. Tyblova, N. Bergsland, S. Hussein, L. Willis, J. Krasensky, M. Vaneckova, Z. Seidl, P. Lelkova, MG. Dwyer, M. Zhang, H. Yu, X. Duan, T. Kalincik, M. Ramanathan,
520    9_
$a OBJECTIVES: To investigate the associations of environmental MS risk factors with clinical and MRI measures of progression in high-risk clinically isolated syndromes (CIS) after the first demyelinating event. METHODS: We analyzed 211 CIS patients (age: 28.9±7.8 years) enrolled in the SET study, a multi-center study of high-risk CIS patients. Pre-treatment samples were analyzed for IgG antibodies against cytomegalovirus (anti-CMV), Epstein Barr virus (EBV) early nuclear antigen-1 (EBNA-1), viral capsid antigen (VCA), early antigen-diffuse (EA-D), 25 hydroxy-vitamin D3 and cotinine levels and HLA DRB1*1501 status. The inclusion criteria required evaluation within 4 months of the initial demyelinating event, 2 or more brain MRI lesions and the presence of two or more oligoclonal bands in cerebrospinal fluid. All patients were treated with interferon-beta. Clinical and MRI assessments were obtained at baseline, 6, 12, and 24 months. RESULTS: The time to first relapse decreased and the number of relapses increased with anti-CMV IgG positivity. Smoking was associated with increased number and volume of contrast-enhancing lesions (CEL) during the 2-year period. The cumulative number of CEL and T2 lesions during the 2-year period was greater for individuals in the highest quartile of anti-EBV VCA IgG antibodies. The percent loss of brain volume was increased for those in the highest quartile of with anti-EBV VCA IgG antibodies. CONCLUSIONS: Relapses in CIS patients were associated with CMV positivity whereas anti-EBV VCA positivity was associated with progression on MRI measures, including accumulation of CEL and T2 lesions and development of brain atrophy.
650    _2
$a dospělí $7 D000328
650    _2
$a protilátky virové $x krev $7 D000914
650    _2
$a kohortové studie $7 D015331
650    _2
$a Cytomegalovirus $x imunologie $7 D003587
650    _2
$a progrese nemoci $7 D018450
650    _2
$a životní prostředí $7 D004777
650    _2
$a virus Epsteinův-Barrové - jaderné antigeny $x imunologie $7 D019309
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a HLA-DRB1 řetězec $x genetika $7 D059811
650    _2
$a lidé $7 D006801
650    _2
$a longitudinální studie $7 D008137
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a roztroušená skleróza $x etiologie $x imunologie $x virologie $7 D009103
650    _2
$a prospektivní studie $7 D011446
650    _2
$a rizikové faktory $7 D012307
650    _2
$a kouření $x škodlivé účinky $7 D012907
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Zivadinov, Robert $u -
700    1_
$a Weinstock-Guttman, Bianca $u -
700    1_
$a Kubala Havrdová, Eva, $u - $d 1955- $7 nlk19990073204
700    1_
$a Qu, Jun $u -
700    1_
$a Tamaño-Blanco, Miriam $u -
700    1_
$a Badgett, Darlene $u -
700    1_
$a Týblová, Michaela $u - $7 xx0121850
700    1_
$a Bergsland, Niels $u -
700    1_
$a Hussein, Sara $u -
700    1_
$a Willis, Laura $u -
700    1_
$a Krásenský, Jan $u - $7 xx0096156
700    1_
$a Vaněčková, Manuela, $u - $d 1973- $7 mzk2007377403
700    1_
$a Seidl, Zdeněk, $u - $d 1950- $7 mzk2004258727
700    1_
$a Lelková, Petra $u - $7 xx0142909
700    1_
$a Dwyer, Michael G $u -
700    1_
$a Zhang, Ming $u -
700    1_
$a Yu, Haoying $u -
700    1_
$a Duan, Xiaotao $u -
700    1_
$a Kalincik, Tomas $u -
700    1_
$a Ramanathan, Murali $u -
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 8, č. 1 (2013), s. e53996
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23320113 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20131002 $b ABA008
991    __
$a 20181023153206 $b ABA008
999    __
$a ok $b bmc $g 995795 $s 830153
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 8 $c 1 $d e53996 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
GRA    __
$p MZ0 $a NT13237
LZP    __
$a Pubmed-20131002

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...